Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure:: relation to functional data and prognosis

被引:44
作者
Jordan, A.
Roldan, V.
Garcia, M.
Monmeneu, I.
de Burgos, F. G.
Lip, G. Y. H.
Marin, F.
机构
[1] Univ Gen Hosp Alicante, Dept Cardiol, Alicante 03002, Spain
[2] Univ Gen Hosp Elche, Dept Cardiol, Elche, Spain
[3] Hosp Morales Maseguer, Dept Haematol & Med Oncol, Murcia, Spain
[4] City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England
关键词
heart failure; metalloproteinases; prognosis;
D O I
10.1111/j.1365-2796.2007.01823.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Jordan A, Roldan V, Garcia M, Monmeneu J, de Burgos FG, Lip GYH, Marin F (University General Hospital of Elche, Elche, Spain; Hospital Morales Meseguer, Murcia, Spain; Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK; and University General Hospital of Alicante, Alicante, Spain). Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med 2007; 262: 385-392. Background. Structural remodelling of left ventricle is a common feature in the progression of congestive heart failure (CHF). Matrix metalloproteinases (MMPs) have been directly implicated as they degrade extracellular proteins. To test the hypothesis that MMP-and its inhibitor, tissue type inhibitor of matrix metalloproteinases (TIMP-1), could be related to functional status and prognosis in CHF, we examined the relationship of MMP-1 and TIMP-1 to peak oxygen consumption (VO2) and peak minute ventilation/carbon dioxide production relationship (VE/VCO2), and assessed their prognostic value. Methods. We studied 50 patients with CHF, who were compared with 53 controls echocardiogram and ergoespirometry were performed, and serum levels of MMP-1 and TIMP-1 were assayed by ELISA. Patients were followed up for 17.5 +/- 8.9 months, and total mortality, readmissions for heart failure and cardiac transplantation were recorded. Results. Patients with CHF had lower levels of MMP-1 (P = 0.027), and higher levels of TIMP-1 and TIMP-1/MMP-1 ratio (both P < 0.01) than controls. TIMP-1 levels and the TIMP-1/MMP-1 ratio correlated negatively with peak VO2 (Spearman, r: -0.51; P = 0.001 and r: -0.42; P = 0.030, respectively). During the follow-up period, 23 patients (47.9%) suffered endpoints - these patients had higher baseline peak VE/VCO2 (P = 0.001), TIMP-1 (P = 0.004), and TIMP-1/MMP-1 ratio values (P = 0.002), whereas MMP-1 levels were lower (P = 0.027). On multivariate analysis, VE/VCO2, MMP-1 levels and age were the only variables independently related to prognosis (all P < 0.05). Conclusion. Poor functional capacity in CHF can be related to abnormal extracellular matrix turnover. Patients who suffered endpoints had more abnormal indices of matrix turnover, where MMP-1 levels showed independent prognostic value.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 30 条
[1]
Peak VO2 and VE/VCO2 slope in patients with heart failure:: A prognostic comparison [J].
Arena, R ;
Myers, J ;
Aslam, SS ;
Varughese, EB ;
Peberdy, MA .
AMERICAN HEART JOURNAL, 2004, 147 (02) :354-360
[2]
Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat [J].
Boixel, C ;
Fontaine, V ;
Rücker-Martin, C ;
Milliez, P ;
Louedec, L ;
Michel, JB ;
Jacob, MP ;
Hatem, SN .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (02) :336-344
[3]
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis -: Results of a randomized trial [J].
Ciulla, MM ;
Paliotti, R ;
Esposito, A ;
Diez, J ;
López, BA ;
Dahlóf, B ;
Nicholls, G ;
Smith, RD ;
Gilles, L ;
Magrini, F ;
Zanchetti, A .
CIRCULATION, 2004, 110 (05) :552-557
[4]
Risk mechanisms in hypertensive heart disease [J].
Frohlich, ED .
HYPERTENSION, 1999, 34 (04) :782-789
[5]
Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure [J].
George, J ;
Patal, S ;
Wexler, D ;
Roth, A ;
Sheps, D ;
Keren, G .
AMERICAN HEART JOURNAL, 2005, 150 (03) :484-487
[6]
Gibbons RJ, 1997, CIRCULATION, V96, P345
[7]
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction [J].
Hayashidani, S ;
Tsutsui, H ;
Shiomi, T ;
Suematsu, N ;
Kinugawa, S ;
Ide, T ;
Wen, J ;
Takeshita, A .
CIRCULATION, 2002, 105 (07) :868-873
[8]
FIBRILLAR COLLAGEN AND MYOCARDIAL STIFFNESS IN THE INTACT HYPERTROPHIED RAT LEFT-VENTRICLE [J].
JALIL, JE ;
DOERING, CW ;
JANICKI, JS ;
PICK, R ;
SHROFF, SG ;
WEBER, KT .
CIRCULATION RESEARCH, 1989, 64 (06) :1041-1050
[9]
MEASURING EXTRACELLULAR-MATRIX TURNOVER IN THE SERUM OF PATIENTS WITH IDIOPATHIC OR ISCHEMIC DILATED CARDIOMYOPATHY AND IMPACT ON DIAGNOSIS AND PROGNOSIS [J].
KLAPPACHER, G ;
FRANZEN, P ;
HAAB, D ;
MEHRABI, M ;
BINDER, M ;
PLESCH, K ;
PACHER, R ;
GRIMM, M ;
PRIBILL, I ;
EICHLER, HG ;
GLOGAR, HD .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (14) :913-918
[10]
Abnormalities of the extracellular degradation of collagen type I in essential hypertension [J].
Laviades, C ;
Varo, N ;
Fernández, J ;
Mayor, G ;
Gil, MJ ;
Monreal, I ;
Díez, J .
CIRCULATION, 1998, 98 (06) :535-540